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Introduction
Protease inhibitor (PR) resistance remains the major lim-
iting in the treatment of HIV infection. Understanding
source of mutation at molecular level is a key of success in
research and drug discovery. The present studies aim to
examine relation between clinical data of drug resistance
and the molecular properties obtained from molecular
dynamics simulations (MD).
Materials and methods
MD simulations of 6 FDA-approved drugs, which are
Lopinavir (LPV), Ritonavir (RTV), Saquinavir (SQV), Indi-
navir (IDV), Amprenavir (APV), and Nelfinavir (NFV),
were performed using AMBER 8. The total inhibitor-
enzyme binding free energy (ΔGtotal) including entropic
contributions of 6 complexes was estimated based on
MM-PB(GB)SA approach. The decomposition free energy
(ΔGDC), representing interaction between inhibitor and
each residue, was calculated and used as the criteria for the
mutation prediction.
Results
In comparison to the expermental binding free energy, the
ΔGtotal for the 6 complexes yields the standard deviation of
± 2.29 kcal/mol, indicating reliability of the method used.
To seek for the correlation between resistance according to
the clinical data and the molecular properties according to
the MD results, the ΔGDC and the structural changes (in
term of the root mean square displacement, RMSD, of
each residue) were evaluated. For simplicity, the notations
F (favourable), U (unfavourable) and S (structure) were,
then, used to represent the residue which gives the ΔGDC
lower than -0.5 Kcal/mol, the ΔGDC higher than 0.5 kcal/
mol and the RMSD higher than 2.0 Å, respectively. In
addition, the notation I (indirect) was used to represent
the residue which locates close to or between the two res-
idues which have F, U and/or S character, i.e., mutation
takes place due to the influence of the F, U and/or S resi-
dues. Table 1 contains the mutated residues which corre-
lated with the level of resistance according to the clinical
data [1] for 6 drugs. The F, U, S and I characteristic of each
residue extracted from the MD trajectories for the 6 com-
plexes were accordingly given. Subscripts a and b indicate
its location in chain A and chain B of the HIV-1 PR, respec-
tively. It can be clearly seen that most of the high-level
resistance (very dark-blue) takes place at the residues
which bind strongly to the inhibitor (F, ΔGDC < -0.5 kcal/
mol) and/or residues which have high RMSD (S, RMSD >
2.0 Å). The data shows also that most of the indirect effect,
I, effects lead to the low-level resistance (dark blue) and
contribute to resistance (light blue). Figure 1 displays
location of the residues for the LPV/enzyme complex with
different levels of resistances; green for F, light-blue for U,
brown for S. The pink and blue CPK represent the mutated
residues which are intermediate and contributes to resist-
ance level, respectively. It appears that the mutated resi-
dues due to the indirect effect are surrounded by those
which have F, U and/or S characters.
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Direct correlation between the experimental drug resist-
ance and the calculated binding free energies obtained
from the MM-PB(GB)SA as well as the structural changes
was observed. Examination was performed for the 6 FDA-
approval inhibitors.
See Table 1 & Figure 1 at http://openwetware.org/wiki/
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